SCHEMBL23888970

SCHEMBL23888970

CC(=O)c1cnn2cc(OCCCC(F)(F)F)ccc12

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 7/20 0.47
▸ MAOB P27338 3/20 0.39
▸ PDE2A O00408 3/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MGAT2 Q10469 1/20 0.36
▸ PPARD Q03181 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17454381 0.94 ROCK2 (0.51) ROCK2PDE2APDE3APDE10AALDH1A1
SCHEMBL19128497 0.90 ROCK2 (0.45) ROCK2MAOBPDE2APTGDR2
SCHEMBL20646991 0.90 ROCK2 (0.45) ROCK2MAOBPDE2APDE3APDE10A
SCHEMBL21947339 0.89 ROCK2 (0.44) ROCK2MAOBPDE2APDE3APDE10A
SCHEMBL17453578 0.86 ROCK2 (0.42) ROCK2PDE2APDE3APDE10AALDH1A1
SCHEMBL23889076 0.85 ROCK2 (0.41) ROCK2PDE2APDE3APDE10AALDH1A1
SCHEMBL19128857 0.84 ROCK2 (0.49) ROCK2PDE2APDE3APDE10AL3MBTL1
SCHEMBL23889045 0.84 ROCK2 (0.42) ROCK2ALDH1A1SMN1; SMN2L3MBTL1PPARD
SCHEMBL24247723 0.83 ROCK2 (0.40) ROCK2PDE2APDE3APDE10AALDH1A1
SCHEMBL20654123 0.83 ROCK2 (0.49) ROCK2PDE2APDE3APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3954681-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2022-02-16 — — EP disclosed
EP-3402790-B1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2021-10-06 — — EP disclosed
Send feedback